Skip to main content Accessibility help
×
Home
  • Print publication year: 2010
  • Online publication date: February 2010

Chapter 18 - Myotonic dystrophy

from Section 3B - Description of muscle disease – specific diseases

References

1. H. Steinert, Myopathologische Beitrage 1. Uber das klinischeund anatomische Bild des Muskelschwunds der Myotoniker. Dtsch. Z. Nervenheilkd. 37 (1909), 58–104.
2. F. Batten, H. Gibb, Myotonia atrophica. Brain 32 (1909), 187–205.
3. J. Thomsen, Tonische krampfe in sillkurlich beweglichen Muskeln infole von erebter paychischer disposition (ataxia muscularis). Arch. Psychiatr. Nervenkr. 6 (1876), 702–718.
4. P. S. Harper, Myotonic Dystrophy. (London: WB Saunders, 2001.)
5. J. D. Brook, M. E. McCurrah, H. G. Harley, et al., Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 68 (1992), 799–808.
6. Y. H. Fu, A. Pizzuti, R. G. Fenwick, Jr., et al., An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255 (1992), 1256–1258.
7. K. Ricker, M. C. Koch, F. Lehmann-Horn, et al., Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 44 (1994), 1448–1452.
8. C. A. Thornton, R. C. Griggs, R. T. Moxley, Myotonic dystrophy with no trinucleotide repeat expansion. Ann. Neurol. 35 (1994), 269–272.
9. R. Moxley, Proximal myotonic myopathy: mini-review of a recently delineated clinical disorder. Neuromuscul. Disord. 6 (1996), 87–93.
10. B. Udd, R. Krahe, C. Wallgren-Petterson, B. Falck, H. Kalimo, Proximal myotonic dystrophy – a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes?Neuromuscul. Disord. 7 (1997), 217–228.
11. L. Ranum, P. Rasmussen, K. Benzow, M. Koob, J. Day, Genetic mapping of a second myotonic dystrophy locus. Nat. Genet. 19 (1998), 196–198.
12. J. W. Day, R. Roelofs, B. Leroy, I. Pech, K. Benzow, L. P. Ranum, Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). Neuromuscul. Disord. 9 (1999), 19–27.
13. C. Liquori, K. Ricker, M. L. Moseley, et al., Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293 (2001), 864–867.
14. IMD Consortium, New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). Neurology54 (2000), 1218–1221.
15. L. Guyant-Marechal, A. Laquerriere, C. Duyckaerts, et al., Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology 67 (2006), 644–651.
16. K. L. Taneja, M. McCurrach, M. Schalling, D. Housman, R. H. Singer, Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol. 128 (1995), 995–1002.
17. C. L. Liquori, K. Ricker, M. L. Moseley, et al., Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293 (2001), 864–867.
18. J. W. Day, K. Ricker, J. F. Jacobsen, et al., Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60 (2003), 657–664.
19. Y. D. Kelkar, S. Tyekucheva, F. Chiaromonte, K. D. Makova, The genome-wide determinants of human and chimpanzee microsatellite evolution. Genome Res. 18 (2008), 30–38.
20. H. Ellegren, Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet. 5 (2004), 435–445.
21. J. B. Redman, R. G. Fenwick, Jr., Y. H. Fu, A. Pizzuti, C. T. Caskey, Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring. J. Am. Med. Assoc. 269 (1993), 1960–1965.
22. C. Savouret, C. Garcia-Cordier, J. Megret, R. H. te Riele, C. Junien, G. Gourdon, MSH2-dependent germinal C T G repeat expansions are produced continuously in spermatogonia from DM1 transgenic mice. Mol. Cell. Biol. 24 (2004), 629–637.
23. L. Foiry, L. Dong, C. Savouret, et al., Msh3 is a limiting factor in the formation of intergenerational CTG expansions in DM1 transgenic mice. Hum. Genet. 119 (2006), 520–526.
24. C. E. Pearson, R. R. Sinden, Alternative structures in duplex DNA formed within the trinucleotide repeats of the myotonic dystrophy and fragile X loci. Biochemistry 35 (1996), 5041–5053.
25. C. E. Pearson, E. K. Nichol, J. D. Cleary, Repeat instability: mechanisms of dynamic mutations. Nat. Rev. Genet. 6 (2005), 729–742.
26. C. J. Howeler, H. F. Bisch, J. P. Geraedts, M. F. Niermeijer, A. Staal, Anticipation in myotonic dystrophy: fact or fiction?Brain 112 (1989), 779–797.
27. H. G. Brunner, H. T. Bruggenwirth, W. Nillesen, et al., Influence of sex of the transmitting parent as well as of parental allele size on the CTG expansion in myotonic dystrophy (DM). Am. J. Hum. Genet. 53 (1993), 1016–1023.
28. G. Jansen, P. Willems, M. Coerwinkel, et al., Gonosomal mosaicism in myotonic dystrophy patients: involvement of mitotic events in (CTG)n repeat variation and selection against extreme expansion in sperm. Am. J. Hum. Genet. 54 (1994), 575–585.
29. V. Yotova, D. Labuda, E. Zietkiewicz, et al., Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum. Genet. 117 (2005), 177–187.
30. S. A. Tishkoff, A. Goldman, F. Calafell, et al., A global haplotype analysis of the myotonic dystrophy locus: implications for the evolution of modern humans and for the origin of myotonic dystrophy mutations. Am. J. Hum. Genet. 62 (1998), 1389–1402.
31. L. Martorell, J. Gamez, M. L. Cayuela, et al., Germline mutational dynamics in myotonic dystrophy type 1 males: allele length and age effects. Neurology 62 (2004), 269–274.
32. N. De Temmerman, K. Sermon, S. Seneca, et al., Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos. Am. J. Hum. Genet. 75 (2004), 325–329.
33. C A. Thornton, K. Johnson, R T. Moxley 3rd.,Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann. Neurol. 35 (1994), 104–7.
34. L. J. Wong, T. Ashizawa, Instability of the (CTG)n repeat in congenital myotonic dystrophy. Am. J. Hum. Genet. 61 (1997), 1445–1448.
35. T. Ashizawa, J. R. Dubel, Y. Harati, Somatic instability of CTG repeat in myotonic dystrophy. Neurology 43 (1993), 2674–2678.
36. L. Martorell, D. G. Monckton, J. Gamez, et al., Progression of somatic CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients. Hum. Mol. Genet. 7 (1998), 307–312.
37. M. Zatz, M. R. Passos-Bueno, A. Cerqueira, et al., Analysis of the CTG repeat in skeletal muscle of young and adult myotonic dystrophy patients: when does the expansion occur? Hum. Mol. Genet. 4 (1995), 401–406.
38. C. Schneider, A. Ziegler, K. Ricker, et al., Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. Neurology 55 (2000), 383–388.
39. R. Krahe, T. Ashizawa, C. Abbruzzese, et al., Effect of myotonic dystrophy trinucleotide repeat expansion on DMPK transcription and processing. Genomics 28 (1995), 1–14.
40. B. M. Davis, M. E. McCurrach, K. L. Taneja, R. H. Singer, D. E. Housman, Expansion of a CUG trinucleotide repeat in the 3′ untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 7388–7393.
41. G. Jansen, P. J. T. A. Groenen, D. Bachner, et al., Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat. Genet. 13 (1996), 316–324.
42. S. Reddy, D. B. J. Smith, M. M. Rich, et al., Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat. Genet. 13 (1996), 325–334.
43. A. Mankodi, E. Logigian, L. Callahan, et al., Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289 (2000), 1769–1773.
44. J. P. Orengo, P. Chambon, D. Metzger, D. R. Mosier, G. J. Snipes, T. A. Cooper, Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 2646–2651.
45. R. J. Osborne, C. A. Thornton, RNA-dominant diseases. Hum. Mol. Genet. 15: Spec No 2 (2006), R162–R169.
46. M. Napierala, W. J. Krzyzosiak, CUG repeats present in myotonin kinase RNA form metastable slippery hairpins. J. Biol. Chem. 272 (1997), 31079–31085.
47. B. Tian, R. J. White, T. Xia, et al., Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA 6 (2000), 79–87.
48. B. H. Mooers, J. S. Logue, J. A. Berglund, The structural basis of myotonic dystrophy from the crystal structure of CUG repeats. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 16626–16631.
49. J. W. Miller, C. R. Urbinati, P. Teng-Umnuay, et al., Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19 (2000), 4439–4448.
50. Y. Yuan, S. A. Compton, K. Sobczak, et al., Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res. 35 (2007), 5474–5486.
51. A. Mankodi, P. Teng-Umnuay, M. Krym, D. Henderson, M. Swanson, C. A. Thornton, Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann. Neurol. 54 (2003), 760–768.
52. M. de Haro, I. Al-Ramahi, B. De Gouyon, et al., MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum. Mol. Genet. 15 (2006), 2138–2145.
53. J. D. Amack, M. S. Mahadevan, The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation. Hum. Mol. Genet. 10 (2001), 1879–1887.
54. M. S. Mahadevan, R. S. Yadava, Q. Yu, et al., Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat. Genet. 38 (2006), 1066–1070.
55. D. L. Black, Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72 (2003), 291–336.
56. A. V. Philips, L. T. Timchenko, T. A. Cooper, Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280 (1998), 737–741.
57. L. P. Ranum, T. A. Cooper, RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 29 (2006), 259–277.
58. X. Lin, J. W. Miller, A. Mankodi, et al., Failure of MBNL1-dependent postnatal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15:13 (2006), 2087–2097.
59. A. Mankodi, M. P. Takahashi, H. Jiang, et al., Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell. 10 (2002), 35–44.
60. N. Charlet, R. S. Savkur, G. Singh, A. V. Philips, E. A. Grice, T. A. Cooper, Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10 (2002), 45–53.
61. T. M. Wheeler, J. D. Lueck, M. S. Swanson, R. T. Dirksen, C. A. Thornton, Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J. Clin. Invest. 117 (2007), 3952–3957.
62. J. D. Lueck, C. Lungu, A. Mankodi, et al., Chloride channelopathy in myotonic dystrophy resulting from loss of post-transcriptional regulation for CLCN1. Am. J. Physiol. Cell. Physiol. 292:4 (2007), C1291–C1297.
63. R. S. Savkur, A. V. Philips, T. A. Cooper, Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29 (2001), 40–47.
64. L. T. Timchenko, J. W. Miller, N. A. Timchenko, et al., Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res. 24 (1996), 4407–4414.
65. S. Michalowski, J. W. Miller, C. R. Urbinati, M. Paliouras, M. S. Swanson, J. Griffith, Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein. Nucleic Acids Res. 27 (1999), 3534–3542.
66. M. Fardaei, K. Larkin, J. D. Brook, M. G. Hamshere, In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res. 29 (2001), 2766–2771.
67. N. A. Timchenko, Z. J. Cai, A. L. Welm, S. Reddy, T. Ashizawa, L. T. Timchenko, RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J. Biol. Chem. 276 (2001), 7820–7826.
68. N. M. Kuyumcu-Martinez, G. S. Wang, T. A. Cooper, Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol. Cell 28 (2007), 68–78.
69. T. H. Ho, B. N. Charlet, M. G. Poulos, G. Singh, M. S. Swanson, T. A. Cooper, Muscleblind proteins regulate alternative splicing. EMBO J. 23 (2004), 3103–3112.
70. M. B. Warf, J. A. Berglund, MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T. RNA 13:12 (2007), 2238–2251.
71. X. Lin, J. W. Miller, A. Mankodi, et al., Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum. Mol. Genet. 15 (2006), 2087–2097.
72. H. Jiang, A. Mankodi, M. S. Swanson, R. T. Moxley, C. A. Thornton, Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum. Mol. Genet. 13 (2004), 3079–3088.
73. R. N. Kanadia, K. A. Johnstone, A. Mankodi, et al., A muscleblind knockout model for myotonic dystrophy. Science 302 (2003), 1978–1980.
74. R. N. Kanadia, J. Shin, Y. Yuan, et al., Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 11748–11753.
75. W. Dansithong, S. Paul, L. Comai, S. Reddy, MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J. Biol. Chem. 280 (2005), 5773–5780.
76. M. Fardaei, M. T. Rogers, H. M. Thorpe, et al., Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum. Mol. Genet. 11 (2002), 805–814.
77. N. A. Timchenko, P. Iakova, Z. J. Cai, J. R. Smith, L. T. Timchenko, Molecular basis for impaired muscle differentiation in myotonic dystrophy. Mol. Cell. Biol. 21 (2001), 6927–6938.
78. A. Ebralidze, Y. Wang, V. Petkova, K. Ebralidse, R. P. Junghans, RNA leaching of transcription factors disrupts transcription in myotonic dystrophy. Science 303 (2004), 383–387.
79. R. S. Yadava, C. D. Frenzel-McCardell, Q. Yu, et al., RNA toxicity in myotonic muscular dystrophy induces NKX2–5 expression. Nat. Genet. 40 (2008), 61–68.
80. T. R. Klesert, A. D. Otten, T. D. Bird, S. J. Tapscott, Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP. Nat. Genet. 16 (1997), 402–406.
81. J. Krol, A. Fiszer, A. Mykowska, K. Sobczak, M. de Metzer, W. J. Kyzyzosiak, Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol. Cell 25:4 (2007), 575–586.
82. W. Chen, Y. Liang, W. Deng, et al., The zinc-finger protein CNBP is required for forebrain formation in the mouse. Development 130 (2003), 1367–1379.
83. J. M. Margolis, B. G. Schoser, M. L. Moseley, J. W. Day, L. P. Ranum, DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum. Mol. Genet. 15 (2006), 1808–1815.
84. A. Botta, S. Caldarola, L. Vallo, et al., Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2). Biochim. Biophys. Acta 1762 (2006), 329–334.
85. P. S. Harper, Congenital myotonic dystrophy in Britain. Clinical aspects. I. Arch. Dis. Child. 50 (1975), 505–513.
86. T. A. O'Brien, P. S. Harper, Course, prognosis and complications of childhood-onset myotonic dystrophy. Dev. Med. Child. Neurol. 26 (1984), 62–67.
87. J. Steyaert, C. de Die-Smulders, J. P. Fryns, E. Goossens, D. Willekens, Behavioral phenotype in childhood type of dystrophia myotonica. Am. J. Med. Genet. 96 (2000), 888–889.
88. C. E. de Die-Smulders, C. J. Howeler, C. Thijs, et al., Age and causes of death in adult-onset myotonic dystrophy. Brain 121:Pt 8 (1998), 1557–1563.
89. J. Mathieu, P. Allard, L. Potvin, C. Prevost, P. Begin, A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 52 (1999), 1658–1662.
90. A. Vihola, G. Bassez, G. Meola, et al., Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 60 (2003), 1854–1857.
91. B. G. Schoser, C. Schneider-Gold, W. Kress, et al., Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 29 (2004), 275–281.
92. J. Mathieu, H. Boivin, D. Meunier, M. Gaudreault, P. Begin, Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56 (2001), 336–340.
93. K. Ricker, M. Koch, F. Lehmann-Horn, et al., Proximal myotonic myopathy: clinical features of a multisystem disorder similar to myotonic dystrophy. Arch. Neurol. 52 (1995), 25–31.
94. E. L. Logigian, E. Ciafaloni, L. C. Quinn, et al., Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 35 (2007), 479–485.
95. A. Mankodi, C. R. Urbinati, Q. P. Yuan, et al., Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet. 10 (2001), 2165–2170.
96. C. Gagnon, Social factors in DM1 in Quebec. In: NIH Burden of Muscle Disease Workshop, 2005.
97. T. Ashizawa, Myotonic dystrophy as a brain disorder. Arch. Neurol. 55 (1998), 291–293.
98. E. Hund, O. Jansen, M. C. Koch, et al., Proximal myotonic myopathy with MRI white matter abnormalities of the brain. Neurology 48 (1997), 33–37.
99. G. Meola, V. Sansone, D. Perani, et al., Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul. Disord. 13 (2003), 813–821.
100. E. Ciafaloni, E. Mignot, V. Sansone, et al., The hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology 70 (2008), 226–230.
101. M. F. Phillips, P. S. Harper, Cardiac disease in myotonic dystrophy. Cardiovasc. Res. 33 (1997), 13–22.
102. J. A. Colleran, R. J. Hawley, E. E. Pinnow, P. F. Kokkinos, R. D. Fletcher, Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy. Am. J. Cardiol. 80 (1997), 1494–1497.
103. G. Bassez, A. Lazarus, I. Desguerre, et al., Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 63 (2004), 1939–1941.
104. W. J. Groh, M. R. Groh, C. Saha, et al., Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N. Engl. J. Med. 358 (2008), 2688–2697.
105. B. G. Schoser, K. Ricker, C. Schneider-Gold, et al., Sudden cardiac death in myotonic dystrophy type 2. Neurology 63 (2004), 2402–2404.
106. A. Lazarus, J. Varin, D. Babuty, F. Anselme, J. Coste, D. Duboc, Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J. Am. Coll. Cardiol. 40 (2002), 1645–1652.
107. K. Wahbi, C. Meune, G. Bassez, et al., Left ventricular non-compaction in a patient with myotonic dystrophy type 2. Neuromuscul. Disord. 18 (2008), 331–333.
108. O. Vignaux, A. Lazarus, J. Varin, et al., Right ventricular MR abnormalities in myotonic dystrophy and relationship with intracardiac electrophysiologic test findings: initial results. Radiology 224 (2002), 231–235.
109. K. M. Baig, M. Discepola, Recurrent capsular opacification after Nd:YAG laser treatment in myotonic dystrophy. Can. J. Ophthalmol. 42 (2007), 489–490.
110. D. K. Newman, Severe capsulorhexis contracture after cataract surgery in myotonic dystrophy. J. Cataract. Refract. Surg. 24 (1998), 1410–1412.
111. R. Osanai, M. Kinoshita, K. Hirose, Eye movement disorders in myotonic dystrophy type 1. Acta Otolaryngol. Suppl. (2007), 78–84.
112. S. Shaunak, R. Orrell, L. Henderson, C. Kennard, Saccades and smooth pursuit in myotonic dystrophy. J. Neurol. 246 (1999), 600–606.
113. I. Modolell, F. Mearin, J. S. Baudet, J. Gamez, C. Cervera, Malagelada, Jr., Pharyngo-esophageal motility disturbances in patients with myotonic dystrophy. Scand. J. Gastroenterol. 34 (1999), 878–882.
114. M. Bellini, P. Alduini, F. Costa, et al., Gastric emptying in myotonic dystrophic patients. Dig. Liver Dis. 34 (2002), 484–488.
115. C. R. Heatwole, J. Miller, B. Martens, R. T. Moxley, 3rd,Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch. Neurol. 63 (2006), 1149–1153.
116. V. Sansone, R. C. Griggs, R. T. Moxley, 3rd,Hypothyroidism unmasking proximal myotonic myopathy. Neuromuscul. Disord. 10 (2000), 165–172.
117. J. L. Geh, A. L. Moss, Multiple pilomatrixomata and myotonic dystrophy: a familial association. Br. J. Plast. Surg. 52 (1999), 143–145.
118. M. R. Draper, J. M. Pickles, Pleomorphic adenoma and myotonic dystrophy: an association?J. Laryngol. Otol. 114 (2000), 985–987.
119. A. E. Saponaro, M. A. Marini, G. C. Rossi, J. G. Casas, Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1. Int. J. Dermatol. 45 (2006), 87–88.
120. R. M. Azurdia, J. L. Verbov, Myotonic dystrophy and basal cell carcinoma-a true association?Br. J. Dermatol. 141 (1999), 941–942.
121. T. Sugio, K. Jinnai, T. Ohara, et al., Myotonic dystrophy associated with insulinoma. Intern. Med. 38 (1999), 504–506.
122. E. Bell, A. R. Lorimer, J. Hinnie, Association between myotonic dystrophy and primary hyperparathyroidism. J. Int. Med. Res. 22 (1994), 296–298.
123. L. Carlin, J. Biller, Myotonic dystrophy and thymoma. J. Neurol. Neurosurg. Psychiatry 44 (1981), 852–853.
124. B. J. Mudge, P. B. Taylor, A. F. Vanderspek, Perioperative hazards in myotonic dystrophy. Anaesthesia 35 (1980), 492–495.
125. G. Gregoratos, J. Abrams, A. E. Epstein, et al., ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 106 (2002), 2145–2161.
126. D. Annane, D. H. Moore, P. R. Barnes, R. G. Miller, Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. Cochrane Database Syst. Rev. 3 (2006), CD003218.
127. H. Kwiecinski, B. Ryniewicz, A. Ostrzycki, Treatment of myotonia with antiarrhythmic drugs. Acta Neurol. Scand. 86 (1992), 371–375.
128. R. C. Griggs, S. Pandya, J. M. Florence, et al., Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 39 (1989), 219–222.
129. E. Vlachopapadopoulou, J. J. Zachwieja, J. M. Gertner, et al., Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy–a clinical research center study. J. Clin. Endocrinol. Metab. 80 (1995), 3715–3723.
130. A. Tollback, S. Eriksson, A. Wredenberg, et al., Effects of high resistance training in patients with myotonic dystrophy. Scand. J. Rehabil. Med. 31 (1999), 9–16.
131. E. Lindeman, P. Leffers, F. Spaans, et al., Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch. Phys. Med. Rehabil. 76 (1995), 612–620.
132. V. Ugalde, E. H. Breslin, S. A. Walsh, H. W. Bonekat, R. T. Abresch, G. T. Carter, Pursed lips breathing improves ventilation in myotonic muscular dystrophy. Arch. Phys. Med. Rehabil. 81 (2000), 472–478.
133. S. P. Kumar, D. Sword, R. K. Petty, S. W. Banham, K. R. Patel, Assessment of sleep studies in myotonic dystrophy. Chron. Respir. Dis. 4 (2007), 15–18.
134. P. Begin, J. Mathieu, J. Almirall, A. Grassino, Relationship between chronic hypercapnia and inspiratory-muscle weakness in myotonic dystrophy. Am. J. Respir. Crit. Care. Med. 156 (1997), 133–139.
135. W. Verpoest, M. De Rademaeker, K. Sermon, et al., Real and expected delivery rates of patients with myotonic dystrophy undergoing intracytoplasmic sperm injection and preimplantation genetic diagnosis. Hum. Reprod. 23 (2008), 1654–1660.
136. N. L. Dean, S. L. Tan, A. Ao, Instability in the transmission of the myotonic dystrophy CTG repeat in human oocytes and preimplantation embryos. Fertil. Steril. 86 (2006), 98–105.
137. N. L. Dean, S. L. Tan, A. Ao, The development of preimplantation genetic diagnosis for myotonic dystrophy using multiplex fluorescent polymerase chain reaction and its clinical application. Mol. Hum. Reprod. 7 (2001), 895–901.
138. S. Fokstuen, J. Myring, C. Evans, P. S. Harper, Presymptomatic testing in myotonic dystrophy: genetic counselling approaches. J. Med. Genet. 38 (2001), 846–850.
139. A. C. Magee, A. E. Hughes, A. Kidd, et al., Reproductive counselling for women with myotonic dystrophy. J. Med. Genet. 39 (2002), E15.
140. L. Martorell, A. M. Cobo, M. Baiget, M. Naudo, J. J. Poza, J. Parra, Prenatal diagnosis in myotonic dystrophy type 1. Thirteen years of experience: implications for reproductive counselling in DM1 families. Prenat. Diagn. 27 (2007), 68–72.
141. M. A. Langlois, C. Boniface, G. Wang, et al., Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J. Biol. Chem. 280 (2005), 16949–16954.
142. D. Furling, G. Doucet, M. A. Langlois, et al., Viral vector producing antisense RNA restores myotonic dystrophy myoblast functions. Gene. Ther. 10 (2003), 795–802.